Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways

Doxorubicin (DOX) is broadly used in treating various malignant tumors. However, its cardiotoxicity limits its clinical use. Roxadustat (FG-4592) is a new hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor and has been approved for treating anemia in chronic kidney diseases (CKD) patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Guangfeng Long, Hongbing Chen, Mengying Wu, Yuanyuan Li, Ling Gao, Songming Huang, Yue Zhang, Zhanjun Jia, Weiwei Xia
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2020-08-01
Schriftenreihe:Frontiers in Pharmacology
Schlagworte:
Roxadustat
doxorubicin cardiotoxicity
HIF-1α
apoptosis
oxidative stress
Online Zugang:https://www.frontiersin.org/article/10.3389/fphar.2020.01191/full
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge